Physician profile
Javed Yousaf
NPI 1700823655
$564.97
in general payments reported to CMS, 2019-2025
16 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $116 · 2020: $70.89 · 2021: $40.62 · 2022: $182 · 2023: $103 · 2024: $52.99.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $156.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $156.14 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $144.02 | 2022-2024 | Freestyle Libre |
| Amarin Pharma, INC. | $70.76 | 2019-2022 | |
| Glaxosmithkline, LLC. | $59.31 | 2019-2022 | |
| Amgen INC. | $42.19 | 2020-2022 | |
| Almatica Pharma LLC | $40.39 | 2022 | |
| Abbvie INC. | $39.30 | 2021-2023 | Ubrelvy |
| Merck Sharp & Dohme LLC | $28.64 | 2019-2020 | |
| Boston Scientific Corporation | $20.42 | 2019 | |
| Novo Nordisk INC | $17.28 | 2023 | Ozempic, Rybelsus |
| Novartis Pharmaceuticals Corporation | $16.14 | 2022 | |
| Astrazeneca Pharmaceuticals Lp | $15.20 | 2024 | Farxiga |
| Sunovion Pharmaceuticals INC. | $15.11 | 2020 | |
| Allergan, INC. | $15.04 | 2019 | |
| Neurocrine Biosciences, INC. | $14.63 | 2020 | |
| Janssen Pharmaceuticals, INC | $14.46 | 2019 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $12.08 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Javed Yousaf listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.